Consun Pharmaceutical continues share repurchases, mandate at 12.5%

Consun Pharmaceutical Group Limited announced ongoing share repurchase activities via a Next Day Disclosure Return dated November 19, 2025. The company repurchased 200,000 ordinary shares on the Exchange on November 19, 2025, at prices ranging from HK$14.33 to HK$14.48, with an aggregate price of HK$2,878,550.

The report also details 24 instances of shares repurchased for cancellation between October 14, 2025, and November 19, 2025, totaling 5,280,000 shares. These repurchases ranged from 2,000 to 505,000 shares per event, representing 0.0002% to 0.0596% of the existing issued shares before the relevant event.

As of November 19, 2025, Consun Pharmaceutical Group’s closing balance of issued shares (excluding treasury shares) stood at 847,983,407. The company's repurchase mandate, approved on May 22, 2025, authorized the repurchase of up to 85,126,334 shares. To date, 10,668,000 shares have been repurchased under this mandate, representing 12.532% of the issued shares at the resolution date. A moratorium for new share issues or treasury share transfers is set until December 19, 2025.